• JNJ-26854165 (Serdemetan) Assay Guide

  2026-09-14

  This scenario-based guide explains how JNJ-26854165 (Serdemetan), SKU A4204, can improve interpretation of proliferation, viability, apoptosis, migration, and radiation-response assays. It connects product-specific handling data with evidence that separates growth inhibition from true cell killing.

• IgSF6, ER Stress, and Antibacterial Macrophages

  2026-09-13

  The reference study identifies endoplasmic reticulum-localized IgSF6 as a regulator of intestinal macrophage stress responses, showing that its deficiency improves antibacterial defense while increasing susceptibility to chemically induced colitis. Its genetic, infection, and pathway-inhibition experiments connect the IRE1α–XBP1 axis and reactive oxygen species to a context-dependent balance between pathogen clearance and intestinal homeostasis.

• BCA Quantification for BPD Mechanistic Research

  2026-09-12

  A translational framework for using bicinchoninic acid protein quantification to strengthen mechanistic studies of LXR signaling, cholesterol overload, and alveolar epithelial apoptosis in bronchopulmonary dysplasia.

• Ginkgo Compound Cocktail Improves Yeast Longevity

  2026-09-11

  A 2026 study combined LC–MS/MS, network pharmacology, and mitochondrial phenotyping to identify a four-compound Ginkgo biloba cocktail that improves stress resistance, mitochondrial performance, and chronological lifespan in yeast. The work supports pathway-guided combination design while showing why extract activity should not be attributed automatically to a single constituent.

• Plerixafor (AMD3100): CXCR4 Assay Design

  2026-09-11

  Plerixafor (AMD3100) is more than a CXCR4 antagonist: it is a mechanistic perturbation tool for linking receptor signaling to migration, mobilization, and tumor-microenvironment phenotypes. This guide explains how to design interpretable assays around the compound while using recent colorectal cancer evidence to sharpen experimental decisions.

• Clozapine N-oxide: Assay Design for Learning

  2026-09-10

  Clozapine N-oxide (CNO) is more than a DREADDs activator: it can help test whether patterned interneuron suppression causes durable cortical plasticity. This article translates recent SST-neuron findings into practical chemogenetic assay decisions, controls, and handling guidance.

• STING–p38 Signaling in Glaucoma Surgery Scarring

  2026-09-10

  Ye et al. identify STING as an upstream regulator of p38 MAPK-associated inflammation and fibrosis after glaucoma filtration surgery. Genetic STING deletion and pharmacological inhibition reduced inflammatory cytokines, fibroblast activation, and collagen deposition in mice, suggesting a mechanistically defined target for improving bleb durability.

• WAY-100635: Interpreting 5-HT1A Pain Assays

  2026-09-09

  WAY-100635 is a selective 5-HT1A antagonist for separating receptor binding, circuit activity, and pain-related behavior. This guide translates cannabidiol pain findings into a rigorous assay strategy while clarifying what pharmacological antagonism can—and cannot—prove.

• Kanamycin Sulfate for Reliable Cell Assays

  2026-09-09

  Learn how Kanamycin Sulfate, SKU A2516, can support controlled bacterial selection, contamination management, and interpretation of cell-based workflows. This scenario-driven guide covers compatibility, preparation, storage, data interpretation, and practical vendor-selection criteria for biomedical laboratories.

• Plerixafor (AMD3100): CXCR4 Research Guide

  2026-09-08

  Plerixafor, also called AMD3100, is a small-molecule CXCR4 antagonist used to study CXCL12 signaling, hematopoietic stem cell mobilization, cancer-cell migration, and immune-cell trafficking. Its strongest established research value is pathway perturbation, while cancer and regenerative applications remain model- and context-dependent.

• Genistein Workflows for Signaling and Autophagy

  2026-09-08

  Use Genistein to separate growth-factor tyrosine kinase signaling from cytoskeleton-dependent responses to mechanical stress. This workflow combines concentration-aware signaling assays, proliferation and apoptosis readouts, and force-induced autophagy controls without overstating cross-domain evidence.

• MK-8745: A Selective Aurora A Inhibitor

  2026-09-07

  MK-8745 enables controlled studies of Aurora A–dependent mitotic arrest, tetraploidy, and apoptosis across cancer models. This workflow-focused guide connects retinoblastoma biology with practical cell-based, lymphoma, and xenograft assay design while emphasizing formulation, controls, and troubleshooting.

• TMEM16F Lipid Scrambling Shapes Ferroptosis Immunity

  2026-09-07

  Yang and colleagues identify TMEM16F-mediated plasma-membrane phospholipid scrambling as a late-stage suppressor of ferroptosis. Their findings connect membrane biophysics with tumor immunology, showing that impaired scrambling intensifies lytic death, slows tumor progression, and improves responses to PD-1 blockade.

• Capsazepine A3279: Reproducible TRPV1 Assays

  2026-09-05

  Capsazepine (SKU A3279) offers a practical, data-guided approach to separating TRPV1-dependent signaling from assay and solvent artifacts. This scenario-based guide covers experimental design, stock preparation, cross-channel interpretation, apoptosis studies, and evidence-based product selection.

• AZD1390 at the Replication–Repair Interface

  2026-09-04

  AZD1390 is a selective ATM kinase inhibitor for examining how DNA damage signaling shapes radiation response. This article connects ATM inhibition with REV1–DHX36 control of G-quadruplex replication while defining practical assay boundaries and translational opportunities.

8322 records 1/555 page Next 12345 下5页 Last page